{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T13:55:58Z","timestamp":1762005358363,"version":"build-2065373602"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,21]],"date-time":"2022-01-21T00:00:00Z","timestamp":1642723200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009947","name":"Merck Sharp & Dohme Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005867","name":"Bangladesh Agricultural Research Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005867","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009702","name":"Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009702","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010877","name":"ViiV Healthcare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010877","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001923","name":"Health Services Research Programme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001923","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004429","name":"University of Crete","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Global Antimicrobial Resistance"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.jgar.2022.01.018","type":"journal-article","created":{"date-parts":[[2022,1,26]],"date-time":"2022-01-26T01:48:35Z","timestamp":1643161715000},"page":"274-281","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Impact of resistance mutations on efficacy of dolutegravir plus rilpivirine or plus lamivudine as maintenance regimens: a cohort study"],"prefix":"10.1016","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6351-2623","authenticated-orcid":false,"given":"Roberta","family":"Gagliardini","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michela","family":"Baccini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7940-1370","authenticated-orcid":false,"given":"Sara","family":"Modica","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2267-1337","authenticated-orcid":false,"given":"Francesca","family":"Montagnani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giacomo","family":"Zanelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"Borghetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4863-1800","authenticated-orcid":false,"given":"Emanuela","family":"Dreassi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5757-8346","authenticated-orcid":false,"given":"Francesca","family":"Lombardi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monica","family":"Pecorari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vanni","family":"Borghi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annapaola","family":"Callegaro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5629-3875","authenticated-orcid":false,"given":"Valeria","family":"Micheli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco Annovazzi","family":"Lodi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Rossetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0344-6281","authenticated-orcid":false,"given":"Maurizio","family":"Zazzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jgar.2022.01.018_bib0001","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1001\/jama.2020.17025","article-title":"Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2020 recommendations of the International Antiviral Society\u2013USA Panel","volume":"324","author":"Saag","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.jgar.2022.01.018_bib0002","unstructured":"EACS Guidelines version 10.1, October 2020. https:\/\/www.eacsociety.org\/guidelines\/guidelines-archive\/."},{"key":"10.1016\/j.jgar.2022.01.018_bib0003","unstructured":"Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents With HIV. Department of Health and Human Services. https:\/\/clinicalinfo.hiv.gov\/sites\/default\/files\/inlin. Accessed date: 01 August 2021."},{"key":"10.1016\/j.jgar.2022.01.018_bib0004","doi-asserted-by":"crossref","DOI":"10.1007\/s11908-019-0691-8","article-title":"Simplifying ARV therapy in the setting of resistance","volume":"21","author":"Pandit","year":"2019","journal-title":"Curr Infect Dis Rep"},{"key":"10.1016\/j.jgar.2022.01.018_bib0005","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1093\/cid\/ciy463","article-title":"Human immunodeficiency virus drug resistance: 2018 recommendations of the International Antiviral Society\u2013USA Panel","volume":"68","author":"G\u00fcnthard","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2022.01.018_bib0006","doi-asserted-by":"crossref","first-page":"e384","DOI":"10.1016\/S2352-3018(17)30069-3","article-title":"Boosted protease inhibitor monotherapy versus boosted protease inhibitor plus lamivudine dual therapy as second-line maintenance treatment for HIV-1-infected patients in sub-Saharan Africa (ANRS12 286\/MOBIDIP): a multicentre, randomised, parallel, open-la","volume":"4","author":"Ciaffi","year":"2017","journal-title":"Lancet HIV"},{"key":"10.1016\/j.jgar.2022.01.018_bib0007","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/ofid\/ofy113","article-title":"Impact of the M184V resistance mutation on virological efficacy and durability of lamivudine-based dual antiretroviral regimens as maintenance therapy in individuals with suppressed HIV-1 RNA: a cohort study","volume":"5","author":"Gagliardini","year":"2018","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.jgar.2022.01.018_bib0008","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.105893","article-title":"Retrospective study on the outcome of two-drug regimens based on dolutegravir plus one reverse transcriptase inhibitor in virologically-suppressed HIV-infected patients","volume":"55","author":"Galizzi","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jgar.2022.01.018_bib0009","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1093\/jac\/dkz009","article-title":"Virological efficacy of dual therapy with lamivudine and dolutegravir in HIV-1-infected virologically suppressed patients: long-term data from clinical practice","volume":"74","author":"Baldin","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2022.01.018_bib0010","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1177\/1060028018761600","article-title":"Dolutegravir plus rilpivirine as a switch option in cART-experienced patients: 96-week data","volume":"52","author":"Capetti","year":"2018","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.jgar.2022.01.018_bib0011","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12981-021-00352-0","article-title":"Virologic outcomes of switching to dolutegravir functional mono- or dual therapy with a non-cytosine nucleoside analog: a retrospective study of treatment-experienced, patients living with HIV","volume":"18","author":"Rolle","year":"2021","journal-title":"AIDS Res Ther"},{"key":"10.1016\/j.jgar.2022.01.018_bib0012","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(17)33095-7","article-title":"Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies","volume":"391","author":"Llibre","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.jgar.2022.01.018_bib0013","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1093\/cid\/ciz1243","article-title":"Efficacy and safety of switching to dolutegravir\/lamivudine fixed-dose 2-drug regimen vs continuing a tenofovir alafenamide-based 3-or 4-drug regimen for maintenance of virologic suppression in adults living with human immunodeficiency virus type 1: phase","volume":"71","author":"Van Wyk","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2022.01.018_bib0014","doi-asserted-by":"crossref","first-page":"e576","DOI":"10.1016\/S2352-3018(19)30149-3","article-title":"Efficacy and safety of dolutegravir\u2013rilpivirine for maintenance of virological suppression in adults with HIV-1: 100-week data from the randomised, open-label, phase 3 SWORD-1 and SWORD-2 studies","volume":"6","author":"Aboud","year":"2019","journal-title":"Lancet HIV"},{"key":"10.1016\/j.jgar.2022.01.018_bib0015","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1093\/jac\/dky093","article-title":"Dolutegravir-based maintenance monotherapy versus dual therapy with lamivudine: a planned 24 week analysis of the DOLAM randomized clinical trial","volume":"73","author":"Blanco","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2022.01.018_bib0016","doi-asserted-by":"crossref","DOI":"10.1186\/s12879-017-2311-2","article-title":"Lamivudine\/dolutegravir dual therapy in HIV-infected, virologically suppressed patients","volume":"17","author":"Maggiolo","year":"2017","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.jgar.2022.01.018_bib0017","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.eclinm.2018.11.005","article-title":"Systematic de-escalation of successful triple antiretroviral therapy to dual therapy with dolutegravir plus emtricitabine or lamivudine in Swiss HIV-positive persons","volume":"6","author":"Diaco","year":"2018","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.jgar.2022.01.018_bib0018","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1177\/1060028017728294","article-title":"Effectiveness, safety, and costs of a treatment switch to dolutegravir plus rilpivirine dual therapy in treatment-experienced HIV patients","volume":"52","author":"Revuelta-Herrero","year":"2018","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.jgar.2022.01.018_bib0019","doi-asserted-by":"crossref","first-page":"2831","DOI":"10.1093\/jac\/dkx233","article-title":"HIV-1 DNA ultra-deep sequencing analysis at initiation of the dual therapy dolutegravir+lamivudine in the maintenance DOLULAM pilot study","volume":"72","author":"Charpentier","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2022.01.018_bib0020","first-page":"1","article-title":"Long-term efficacy of dolutegravir plus lamivudine for maintenance of HIV viral suppression in adults with and without historical resistance to lamivudine: week 96 results of ART-PRO pilot study","author":"Rial-Crestelo","year":"2021","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2022.01.018_bib0021","article-title":"Impact of M184V on the virological efficay of switch to 3TC\/DTG in real life","author":"Santoro","year":"2021","journal-title":"Abstr Present CROI, March 6-10 2021"},{"key":"10.1016\/j.jgar.2022.01.018_bib0022","doi-asserted-by":"crossref","first-page":"e200","DOI":"10.1093\/cid\/ciaa313","article-title":"Shall we dance? Extending TANGO's results to clinical practice","volume":"71","author":"Borghetti","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2022.01.018_bib0023","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1111\/hiv.12506","article-title":"Efficacy and safety of dolutegravir and rilpivirine dual therapy as a simplification strategy: a cohort study","volume":"18","author":"Gantner","year":"2017","journal-title":"HIV Med"},{"key":"10.1016\/j.jgar.2022.01.018_bib0024","first-page":"111","article-title":"2019 update of the drug resistance mutations in HIV-1","volume":"27","author":"Wensing","year":"2019","journal-title":"Top Antivir Med"},{"key":"10.1016\/j.jgar.2022.01.018_bib0025","doi-asserted-by":"crossref","first-page":"2837","DOI":"10.1002\/sim.5705","article-title":"The performance of different propensity score methods for estimating marginal hazard ratios","volume":"32","author":"Austin","year":"2013","journal-title":"Stat Med"},{"key":"10.1016\/j.jgar.2022.01.018_bib0026","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1002\/sim.8008","article-title":"Propensity-score matching with competing risks in survival analysis","volume":"38","author":"Austin","year":"2019","journal-title":"Stat Med"},{"key":"10.1016\/j.jgar.2022.01.018_bib0027","unstructured":"R Core Team. R: A Language and Environment for Statistical Computing. Vienna, Austria; 2016. Available from: https:\/\/www.R-project.org."},{"year":"2019","series-title":"Stata Statistical Software: Release 16","key":"10.1016\/j.jgar.2022.01.018_bib0028"},{"key":"10.1016\/j.jgar.2022.01.018_bib0029","doi-asserted-by":"crossref","DOI":"10.1111\/hiv.13050","article-title":"Effectiveness and safety of dolutegravir two-drug regimens in virologically suppressed people living with HIV: a systematic literature review and meta-analysis of real-world evidence","author":"Punekar","year":"2021","journal-title":"HIV Med"},{"key":"10.1016\/j.jgar.2022.01.018_bib0030","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/5923256","article-title":"Real-world experience with dolutegravir-based two-drug regimens","author":"Ward","year":"2020","journal-title":"AIDS Res Treat"},{"key":"10.1016\/j.jgar.2022.01.018_bib0031","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.12688\/f1000research.15995.2","article-title":"Virologic failure and HIV drug resistance on simplified, dolutegravir-based maintenance therapy: systematic review and meta-analysis","volume":"7","author":"Wandeler","year":"2019","journal-title":"F1000Research"}],"container-title":["Journal of Global Antimicrobial Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716522000224?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716522000224?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T09:57:20Z","timestamp":1761991040000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213716522000224"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":31,"alternative-id":["S2213716522000224"],"URL":"https:\/\/doi.org\/10.1016\/j.jgar.2022.01.018","relation":{},"ISSN":["2213-7165"],"issn-type":[{"type":"print","value":"2213-7165"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of resistance mutations on efficacy of dolutegravir plus rilpivirine or plus lamivudine as maintenance regimens: a cohort study","name":"articletitle","label":"Article Title"},{"value":"Journal of Global Antimicrobial Resistance","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgar.2022.01.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Ltd on behalf of International Society for Antimicrobial Chemotherapy.","name":"copyright","label":"Copyright"}]}}